A month has gone by since the last earnings report for Achillion Pharmaceuticals (ACHN). Shares have lost about 1.4% in that time frame, underperforming the S&P 500.

Achillion investors are probably shaking their heads wondering what's wrong with their company following Johnson & Johnson 's acquisition of the privately held Alios for $1.7 billion this week. On ...

BOSTON (MarketWatch) -- Shares of Achillion Pharmaceuticals achn were up 11% at $6.65 early Wednesday after it priced a public stock offering modestly below Tuesday's closing price of $6.01 ...

AMSTERDAM, the Netherlands, April 22, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the presentation of updated results from the ongoing phase 2 ‘604 ...

NEW HAVEN, Conn., March 2, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging ...

NEW HAVEN, Conn., Oct. 23, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) reported today Phase 2b data on JNJ-4178, the triple combination consisting of odalasvir, AL-335 ...

Achillion Pharmaceuticals Inc., expecting clinical data on three experimental hepatitis C therapies, is in “advanced discussions” with potential partners and acquirers, Chief Executive Officer ...